Search Results

Your search for Hagop Kantarjian, MD, and Robert Chapman, MD,Hagop Kantarjian, MD, and Robert Chapman, MD matches 2 pages

Showing 1 - 2

By Robert Manges, MD / March 25, 2016

340B Drug Pricing Program Revisited

I have to disagree with some of the conclusions drawn by Drs. Hagop Kantarjian and Robert Chapman in their editorial on the 340B Drug Pricing Program, which appeared in the January 25 issue of The ASCO Post. Although I’m sure I’m not the best person to provide an alternate view, I do feel strongly...

cost of care

By Hagop Kantarjian, MD, and Robert Chapman, MD / January 25, 2016

The 340B Drug Pricing Program: Background, Concerns, and Solutions

The 340B Drug Pricing Program was created by Congress through the Veterans Health Care Act of 1992 to allow some health-care entities—including safety-net providers with large shares of uninsured and low-income patients and other “covered entities”—to obtain drugs at discounted prices.1,2 Congress...

Nov

Today In Oncology

Search Results

Your search for Hagop Kantarjian, MD, and Robert Chapman, MD,Hagop Kantarjian, MD, and Robert Chapman, MD matches 2 pages

340B Drug Pricing Program Revisited

The 340B Drug Pricing Program: Background, Concerns, and Solutions

What Is the Impact of a Colon or Colorectal Cancer Diagnosis on Younger Adults?

International Cancer Organizations Present Collaborative Work During Oncology Event in China

Is There a Role for Neoadjuvant Chemotherapy in HR-Positive, HER2-Negative Early Breast Cancer?

Suicide-Related Mortality in Male AYA Cancer Survivors

Four-Year Asian Subpopulation Data From the CheckMate 816 Trial of Neoadjuvant Nivolumab Plus Chemotherapy in Resectable NSCLC